by Beth Cullen | Apr 11, 2022 | Investor Relations, Japan Focus
Control Bionics is all set to launch its NeuroNode Trilogy technology in Japan in partnership with major assistive technology distributor, Double R&D Co Ltd, under an initiative led by CBL’s Japanese executive, Erica Kitayama. CBL has advanced the deal to...
by Beth Cullen | Mar 9, 2022 | Investor Relations
Having achieved a year of strong growth, Control Bionics (ASX:CBL) is forging ahead in the current year to level up its momentum as it aims to emerge as a leading player in the innovative augmentative communications and control (ACC) device space. The...
by Beth Cullen | Feb 17, 2022 | Education, Investor Relations
According to the recent paper published by biomedical engineering student Lester Lo at RMIT University, eye gaze combined with EMG switching outperformed traditional eye gaze AAC systems. The study was designed to test the speed and accuracy of an eye gaze...
by Beth Cullen | Feb 2, 2022 | Investor Relations
Featured in a writeup by Kalkine Media, Control Bionics is proud to report a 34% sales revenue growth in the December quarter. The article highlighted Control Bionics’ strong sales in the US market, robust pipeline in Australia, two new product launches, and a...
by Beth Cullen | Dec 28, 2021 | In the News, Investor Relations, USA Focus
This year, Control Bionics was honored to be included in the annual listing of 20 companies that are at the forefront of providing Medtech Year End Special Solutions and impacting the industry. CEO Rob Wong spoke with Medtech Outlook about the background of Control...
by Beth Cullen | Dec 13, 2021 | Investor Relations
This week, Control Bionics CEO Rob Wong sat down with Bulls N’ Bears host Matt Birney to discuss the company’s innovative technology and market growth. Click here to listen to the full interview. Matt Birney: As I see it, Control Bionics essentially gives...
